Search clinical trials for: cMET negative NSCLC

Total 9352 results

Novartis Pharmaceuticals

Terminated

Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer

Non Small Cell Lung Cancer

Spain, Singapore, Germany, Switzerland, Australia, France, Italy, United States
Shanghai Pulmonary Hospital, Shanghai, China

Recruiting

Cadonilimab Plus Chemotherapy as First-line Treatment for PD-L1 Negative NSCLC (LungCadX)

NSCLC

China
Changzhou No.2 People's Hospital

Not yet recruiting

FMT+Immunotherapy+Chemotherapy as First-line Treatment for Driver-gene Negative Advanced NSCLC

Non-small Cell Lung Cancer
Eli Lilly and Company
Loxo Oncology, Inc.

Recruiting

A Study of LY4170156 in Participants With Selected Advanced Solid Tumors

Uterine Cervical Neoplasms | Carcinoma, Non-Small-Cell Lung | Colorectal Neoplasms | Ovarian Neoplasms | Endometrial Neoplasms | Triple Negative Breast Neoplasms | Pancreatic Neoplasm

United States
University of Alabama at Birmingham

Not yet recruiting

DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC

Non Small Cell Lung Cancer

United States
The First Affiliated Hospital, Guangzhou University...

Not yet recruiting

A Single-arm Pilot Study of Tislelizumab Combined With Anlotinib in Patients With Advanced NSCLC With Driver-negative After Progression to Immunotherapy

Advanced NSCLC
Fusion Pharmaceuticals Inc.
AstraZeneca

Not yet recruiting

A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours

Advanced Solid Tumor | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Pancreatic Ductal Adenocarcinoma | Metastatic Colorectal Carcinoma

United States, Canada
Qian Chu
Akeso Pharmaceuticals, Inc.

Recruiting

Cadonilimab (AK104) Plus Chemotherapy as First-line Treatment in Non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients With Programmed Cell Death Ligand 1 (PD-L1) Negative (ACHELOUS)

Carcinoma, Non-Small-Cell Lung

China
Amgen

Recruiting

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

Non-Small Cell Lung Cancer (NSCLC)

United States, Australia, Netherlands, Taiwan, Korea, Republic of, United Kingdom, Spain, Austria, Japan, Switzerland, Sweden, France, Czechia, Italy, Portugal, Hong Kong, Thailand, Singapore, Bulgaria, Turkey, Argentina, Belgium, G... and more
Arcus Biosciences, Inc.

Recruiting

Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers (ARC-25)

Cervical Cancer | Gastric Cancer | Esophageal Cancer | Ovarian Cancer | Bladder Cancer | Advanced Cancer | Non-Small Cell Lung Cancer (NSCLC) | Advanced Malignancies | Renal Cell Carcinoma (RCC) | Triple Negative Breast Cancer (TNBC) | Head and Neck Squamous Cell Carcinoma (HNSCC) | Gastroesophageal-junction...

United States, Australia
Bristol-Myers Squibb

Recruiting

A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors

Advanced Solid Tumors

Spain, United States, Netherlands, France, Italy, Belgium
Sapience Therapeutics

Recruiting

A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors

Hepatocellular Carcinoma | Pancreatic Cancer | Ovarian Cancer | Cholangiocarcinoma | Triple Negative Breast Cancer | Metastatic Melanoma | Colon Cancer | Synovial Sarcoma | Breast Cancer Metastatic | Metastatic Colon Cancer | Melanoma Stage IV | Melanoma Recurrent | TNBC - Triple-Negative Breast Cancer | NSCLC, Metastatic and other conditions

United States
Nikolaj Frost MD
Roche Pharma AG; Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus...

Recruiting

Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma (ANTELOPE)

Non-Small Cell Lung Cancer Metastatic

Germany
Mythic Therapeutics

Recruiting

Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer | NSCLC | Advanced Non-Small Cell Lung Cancer | NSCLC Stage IV | NSCLC Stage IIIB | Advanced Non-Small Cell Squamous Lung Cancer | Advanced Non-Small Cell Non-Squamous Lung Cancer

United States, Australia, Korea, Republic of, United Kingdom
National Cancer Institute (NCI)

Recruiting

Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung | Non-Small Cell Lung Cancer | Non-Small Cell Lung Carcinoma | Carcinomas

United States
BeiGene

Recruiting

A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer | Metastatic Non-small Cell Lung Cancer

United States, China, Australia, Spain, Malaysia, Italy, Canada, Thailand, Georgia, Brazil, Korea, Republic of, Singapore, Moldova, Republic of, Romania
Intima Bioscience, Inc.

Not yet recruiting

CISH Inactivated TILs in the Treatment of NSCLC (CheckCell-2)

Carcinoma, Non-Small-Cell Lung | Adenocarcinoma of Lung | Stage IV Non-small Cell Lung Cancer | Squamous Cell Lung Cancer | Metastatic Non Small Cell Lung Cancer | Large Cell Lung Cancer

United States
Novartis Pharmaceuticals

Recruiting

A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers

Carcinoma, Renal Cell | Carcinoma, Non-Small-Cell Lung | Nasopharyngeal Carcinoma | Carcinoma, Ovarian Epithelial | Mesothelioma | Squamous Cell Carcinoma of Head and Neck | Triple Negative Breast Neoplasms | Anal Cancer | Cutaneous Melanoma | Esophagogastric Cancer | Carcinoma, Thymic | High Microsatellite...

Italy, Spain, Singapore, Germany, Taiwan, Japan, Canada, Hong Kong, United States
Monte Rosa Therapeutics, Inc

Recruiting

Study of Oral MRT-2359 in Selected Cancer Patients

NSCLC | Prostate Cancer | SCLC | DLBCL | High Grade Neuroendocrine Cancer | L-MYC and N-MYC Amplified Solid Tumors | NSCLC With High or Low L-MYC or N-MYC Expression | HR-positive, HER2-negative Breast Cancer

United States, Canada
Bayer

Recruiting

A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors

Advanced Solid Tumors

United States, Canada, Singapore, United Kingdom, Belgium
Shanghai EpimAb Biotherapeutics Co., Ltd.
Labcorp Corporation of America Holdings, Inc

Not yet recruiting

EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Advanced Lung Non-Small Cell Carcinoma | EGFR Mutation-Related Tumors

United States, China
Affiliated Cancer Hospital & Institute of Guangzhou...

Not yet recruiting

Recombinant Human Angioendostatin /PD-1 Mab Combined With First-line Chemotherapy in the Treatment of Driver Gene Negative Advanced NSCLC

Non Small Cell Lung Cancer | Endostatin

China
Genor Biopharma Co., Ltd.

Recruiting

A Safety, Tolerability, PK and Preliminary Activity Study of GB263T in Advanced NSCLC and Other Solid Tumor

NSCLC | Other Solid Tumors

Australia
Lyell Immunopharma, Inc.

Recruiting

A Study to Investigate LYL797 in Adults With Solid Tumors

Advanced Breast Cancer | NSCLC | Non Small Cell Lung Cancer | Triple Negative Breast Cancer | Non-small Cell Lung Cancer | Advanced Lung Carcinoma | Non Small Cell Lung Cancer Metastatic | NSCLC Stage IV | Recurrent Breast Cancer | TNBC - Triple-Negative Breast Cancer | Relapsed Cancer | NSCLC, Recurrent | Recurrent... and other conditions

United States
Seagen Inc.

Recruiting

A Study of SGN-PDL1V in Advanced Solid Tumors

Melanoma | Carcinoma, Non-Small-Cell Lung | Gastric Cancer | Ovarian Neoplasms | Squamous Cell Carcinoma of the Head and Neck | Triple Negative Breast Neoplasms | Esophageal Squamous Cell Carcinoma

United States, Spain, Italy, Canada, United Kingdom, France, Belgium, Germany, Netherlands
Seagen Inc.

Recruiting

A Study of SGN-B7H4V in Advanced Solid Tumors

Carcinoma, Non-Small-Cell Lung | Adenoid Cystic Carcinoma | Ovarian Neoplasms | Fallopian Tube Neoplasms | Peritoneal Neoplasms | Endometrial Neoplasms | Cholangiocarcinoma | Triple Negative Breast Neoplasms | Gallbladder Carcinoma | HER2 Negative Breast Neoplasms | Hormone Receptor Positive Breast Neoplasms

United States, Spain, Canada, United Kingdom, Germany, Italy
Tongji University

Recruiting

A Phase III Trial of Neoadjuvant Sintilimab and Chemotherapy for NSCLC Harboring No Driver Mutations

NSCLC, Stage IIIA | EGF-R Negative Non-Small Cell Lung Cancer | ALK Negative NSCLC

China
Nurix Therapeutics, Inc.

Recruiting

A Study of NX-1607 in Adults With Advanced Malignancies

Cervical Cancer | Gastric Cancer | Head and Neck Squamous Cell Carcinoma | Non-small Cell Lung Cancer (NSCLC) | Metastatic Urothelial Carcinoma | Ovarian Cancer, Epithelial | Metastatic Castration-resistant Prostate Cancer (mCRPC) | Triple Negative Breast Cancer (TNBC) | Malignant Pleural Mesothelioma... and other conditions

United States, United Kingdom
China Resources Sanjiu Medical & Pharmaceutical...

Not yet recruiting

Jinfukang Oral Liquid Combined With Chemotherapy for Treating Driver Gene-negative Advanced NSCLC

Non Small Cell Lung Cancer
Medicenna Therapeutics, Inc.
Merck Sharp & Dohme LLC

Recruiting

A Beta-only IL-2 ImmunoTherapY Study (ABILITY-1)

Clear Cell Renal Cell Carcinoma | Cervical Cancer | Gastric Cancer | Esophageal Cancer | Ovarian Cancer | Fallopian Tube Cancer | Solid Tumor | Squamous Cell Carcinoma of Head and Neck | Bladder Cancer | Skin Cancer | Triple Negative Breast Cancer | Advanced Solid Tumor | Primary Peritoneal Cancer | Endometrial Carcinoma and other conditions

United States, Australia, Korea, Republic of, Canada
Cancer Research UK
Hummingbird Bioscience

Recruiting

HMBD-001 in Advanced HER3 Positive Solid Tumours

Melanoma | Cervical Cancer | Gastric Cancer | Pancreatic Cancer | Ovarian Cancer | Hepatocellular Carcinoma (HCC) | Bladder Cancer | Triple Negative Breast Cancer | Endometrial Cancer | Castration-resistant Prostate Cancer | Non-small Cell Lung Cancer (NSCLC) | Oesophageal Cancer | RAS Wild Type Colorectal Cancer | Squamous Cell Cancer of the Head and Neck

United Kingdom
Tang-Du Hospital

Recruiting

Toripalimab in Combination With Platinum-based Chemotherapy for Mutation-negative Stage IV Oligometastatic NSCLC

NSCLC Stage IV | Oligometastasis

China
Hubei Cancer Hospital

Recruiting

Toripalimab Combined With Anlotinib and SBRT in Patients With Untreated Brain Metastases of Driven Gene-negative NSCLC

NSCLC

China
Betta Pharmaceuticals Co., Ltd.

Recruiting

Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors

Head and Neck Cancer | Colorectal Cancer | Non-Small Cell Lung Cancer | Solid Tumor

China
Bristol-Myers Squibb

Recruiting

A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors

Melanoma | Carcinoma, Renal Cell | Cervical Cancer | Pancreatic Adenocarcinoma | Ovarian Neoplasms | Squamous Cell Carcinoma of Head and Neck | Triple Negative Breast Neoplasms | Urothelial Carcinoma | Microsatellite Stable Colorectal Cancer | Non-Small-Cell Lung Cancer | Gastric/Gastroesophageal Junction...

United States, Australia, Italy, Germany, Spain, Canada, Israel, Japan
Shanghai Pulmonary Hospital, Shanghai, China

Not yet recruiting

Adjuvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) NSCLC (LungMate-008)

Non Small Cell Lung Cancer
Guangdong Association of Clinical Trials

Not yet recruiting

Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLC

Non-Small-Cell Lung Cancer
Transgene
Merck Sharp & Dohme LLC; BioInvent International AB

Recruiting

A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors

Melanoma | Soft Tissue Sarcoma | Non Small Cell Lung Cancer | Metastatic Cancer | Triple Negative Breast Cancer | Merkel Cell Carcinoma

France, Belgium
Fujian Cancer Hospital

Not yet recruiting

Toripalimab as Maintenance Therapy in Patients With Driver-gene Negative Advanced NSCLC After First-line Chemotherapy

NSCLC Stage IV

China
Sichuan Baili Pharmaceutical Co., Ltd.
SystImmune Inc.

Recruiting

A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors

Solid Tumor

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

The Study of Exosome EML4-ALK Fusion in NSCLC Clinical Diagnosis and Dynamic Monitoring

Untreated Advanced NSCLC Patients | FISH Identified ALK Fusion Positive or Negative

China
Li Zhang, MD

Not yet recruiting

JS001 Combination Therapy in NSCLC Negative Driving Gene After First-line Chemotherapy.

Non-small Cell Lung Cancer

China
Seagen Inc.

Recruiting

A Study of SGN-B6A in Advanced Solid Tumors

Uterine Cervical Neoplasms | Stomach Neoplasms | Urinary Bladder Neoplasms | Ovarian Neoplasms | Squamous Cell Carcinoma of Head and Neck | Carcinoma, Non-Small Cell Lung | Esophageal Adenocarcinoma | Esophageal Squamous Cell Carcinoma | Gastroesophageal Junction Adenocarcinoma | HER2 Negative Breast Neoplasms and other conditions

United States, Spain, United Kingdom, France, Switzerland
Immunocore Ltd

Recruiting

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

Select Advanced Solid Tumors

United States, Belgium, Korea, Republic of, Australia, Germany, United Kingdom, Spain, Poland, Austria, Brazil, Canada, New Zealand, France, Italy, Netherlands, Switzerland
Astellas Pharma Global Development, Inc.
Merck Sharp & Dohme LLC; Seagen Inc.

Recruiting

A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

Locally Advanced or Metastatic Malignant Solid Tumors

United States, Japan, Canada
BicycleTx Limited

Recruiting

Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression

Head and Neck Cancer | Ovarian Cancer | Triple Negative Breast Cancer | Non-small Cell Lung Cancer | Advanced Solid Tumor Historically Known for High EphA2 Expression | Urothelial Cancer | Gastric/Upper Gastrointestinal Cancer

United States, Belgium, Korea, Republic of, Spain, United Kingdom
Shanghai EpimAb Biotherapeutics Co., Ltd.
Covance

Recruiting

A Dose Escalation With Expansion Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors

Neoplasms | Neoplasm Metastasis | Non-Small-Cell Lung Cancer

United States, China
Nanobiotix

Recruiting

NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy

Metastatic Renal Cell Carcinoma | Squamous Cell Carcinoma of Head and Neck | Radiotherapy | Immunotherapy | Microsatellite Instability-High Solid Malignant Tumour | Metastasis From Malignant Tumor of Liver | Metastasis From Malignant Tumor of Cervix | Metastasis From Malignant Melanoma of Skin (Disorder) and other conditions

United States
The Netherlands Cancer Institute
Bristol-Myers Squibb

Recruiting

18F-PD-L1 PET/CT in Nivolumab Treated Patients With NSCLC

NSCLC Stage IV

Netherlands
BioAtla, Inc.

Recruiting

CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)

Melanoma | Head and Neck Cancer | Non Small Cell Lung Cancer | Triple Negative Breast Cancer

United States, Hong Kong, Taiwan, Spain, Greece, Germany, Italy, Poland

Search clinical trials for: cMET negative NSCLC

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Qatar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations